27 Oct 2016 16:10
Premaitha Health Plc
("Premaitha" or the "Company")
Result of AGM
Manchester, UK - 27 October 2016 - Premaitha announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed.
For more information, please contact:
Premaitha Health plc | Tel: +44 (0) 161 667 1053 |
Dr Stephen Little, Chief Executive Office |
|
Barry Hextall, Chief Financial Officer |
|
Joanne Cross, Head of Marketing |
|
investors@premaitha.com |
|
|
|
Cairn Financial Advisers LLP (Nomad) | Tel: +44 (0) 20 7213 0880 |
Liam Murray / Jo Turner |
|
|
|
finnCap (Broker) | Tel: +44 (0) 20 7220 0500 |
Adrian Hargrave / Scott Mathieson (Corporate Finance) |
|
Tony Quirke (Corporate Broking) |
|
|
|
Vigo Communications | Tel: +44 (0) 20 7830 9704 |
Ben Simons / Fiona Henson / Antonia Pollock |
|
premaitha@vigocomms.com |
|
About Premaitha
Premaitha is a molecular diagnostics company which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women.
Premaitha's lead test - the IONA® test - was launched in February 2015 and is the leading CE marked complete system which estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The IONA® test is performed on the mother's blood sample - which contains traces of fetal DNA - and then analysed using next generation DNA sequencing technology from ThermoFisher Scientific.
Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary stressful and invasive follow-up diagnostic procedures which are costly, resource intensive and carry a risk of miscarriage.
Non-invasive prenatal screening is an emerging, multi-billion dollar global market and Premaitha's complete CE marked system enables laboratories and health care practitioners to offer an approved, non-invasive prenatal screening system in-house.
YGEN.L (YGEN)